Skip to main content
Fig. 2 | Cancer Cell International

Fig. 2

From: Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways

Fig. 2

SKBR3, ZR75, and HNME-E6/E7 cell viability. The effects of different concentrations of dasatinib (DA) (0,1,5,7,10,20 µM), BMS-202 (0,1,5,7,10,20 µM), and combination therapy of both on cell viability of HER2-positive breast cancer cell lines (a) SKBR3 and (b) ZR75. (c) The effects of different concentrations of a combination of DA (0,1,5,10,15,20,30 µM) and BMS-202 (0,1,5,10,15,20,30 µM) on cell viability of human immortalized mammary epithelial (HNME-E6/E7) cells. Cells were treated for 48 h. Data indicate an inverse relationship between concentrations of DA and BMS-202, individually and in combination on cell viability in both cancer cell lines, in comparison to HNME-E6/E7 cells. Data are expressed as a percentage of growth ± SEM

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us